Barrow, Hanley, Mewhinney & Strauss’s 10x Genomics TXG Stock Holding History

Barrow, Hanley, Mewhinney & Strauss’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.13K	Buy	+160	New	+$4.19K	﹤0.01%	280

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Barrow, Hanley, Mewhinney & Strauss's TXG Position: Q2 2026 in Review

Barrow, Hanley, Mewhinney & Strauss opened a new position in 10x Genomics (TXG) in Q2 2026: 160 shares worth $6.13K. The stake represents ﹤0.01% of the portfolio and ranks #280 among its holdings.

390 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Barrow, Hanley, Mewhinney & Strauss held 160 shares of 10x Genomics worth $6.13K as of Q2 2026.
10x Genomics was a new Barrow, Hanley, Mewhinney & Strauss position in Q2 2026.
10x Genomics made up ﹤0.01% of Barrow, Hanley, Mewhinney & Strauss's portfolio in Q2 2026, its #280 holding.
390 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Barrow, Hanley, Mewhinney & Strauss's 13F filing for Q2 2026, filed 12 Aug 2026.